The Prevalence of Antinuclear Antibodies in Patients with Sarcoidosis

Table 1

Demographic, clinical, and laboratory features in patients with sarcoidosis.

Features	Patients, (%)
Age, mean, year	45.2 years
Disease duration, mean, year	3.5 years
Sex (women/men)	32/10
Erythema nodosum	20 (47.6%)
Uveitis	3 (7.1%)
Myositis	1 (2.3%)
Neurosarcoidosis	1 (2.3%)
Arthritis	32 (76.2%)
Elevated serum ACE level (normal 8–52 U/L)	15 (35.7%)
Antinuclear antibody positivity	12 (28.5%)
RF positivity (normal < 14 IU/mL)	7 (16.6%)
Elevated serum C3 (normal 0.9–1.8 g/L)	1 (2.3%)
Elevated serum C4 (normal 0.1–0.4 g/L)	3 (7.1%)
Stage 1 sarcoidosis	12 (28.5%)
Stage 2 sarcoidosis	22 (52.4%)
Stage 3/4 sarcoidosis	4/4 (9.5%)